Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Create Team to Discuss How to Promote Development of Cutting-Edge Technology
December 7, 2009
- Eisai Launches Sedative-Hypnotic Lusedra in the US
November 30, 2009
- Astellas Applies for ASP8825 for RLS in Japan
November 30, 2009
- Vibativ Launched in the US: Astellas
November 30, 2009
- FDA Warns against Concurrent Use of Omeprazole and Plavix
November 30, 2009
- Alexion Pharma to Hire Up to 13 MCCs in Japan: President Strenger
November 30, 2009
- Sales of Ethical Drugs Up 6.2% Driven by Flu-Related Products: Crecon
November 30, 2009
- IMS Health to Be Acquired by TPG and CPP Investment Board
November 30, 2009
- TAK-438 Enters PII for Reflux Esophagitis: Takeda
November 30, 2009
- Daiichi Sankyo Wins Levofloxacin Patent Lawsuit in the UK
November 30, 2009
- Liraglutide Prevents Weight Gain in Japanese Patients
November 30, 2009
- Greater Efforts Needed to Foster Ventures: Mr Kawakami
November 30, 2009
- Record Productivity Achieved for CHO Cells with BI-HEX Platform: BI
November 30, 2009
- Rasilez's Benefits for Hypertension Recognized by Updated ESH GL: Novartis
November 30, 2009
- Over 60% of Consumers Desire Vaccination against New-Type Flu but with Domestic Vaccines
November 30, 2009
- Miraka HD: Operating Profits Up 48% Driven by Flu-Related Products
November 30, 2009
- Megapharmas Will Flee from Japan Unless Gov't Promotes Industry: Mr Dunoyer
November 30, 2009
- Pfizer Embarks on Generics Business in Japan
November 30, 2009
- Taisho Acquires BMS's OTC Drugs Business in Asia, Pacific
November 30, 2009
- Combined Sales of 21 JPMA Member Companies Up 1.6%
November 30, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…